|
Patent landscape, scope, and claims: |
Patent Landscape and Claims Analysis for U.S. Patent 9,682,061
What Does Patent 9,682,061 Cover?
U.S. Patent 9,682,061, titled "Methods of treating or preventing disease by administering a sirtuin modulator", was granted on June 20, 2017. It primarily relates to pharmaceutical compositions involving sirtuin modulators used for treating or preventing various diseases, notably age-related conditions, metabolic disorders, and neurodegenerative diseases. The patent's scope emphasizes novel methods of administration, specific sirtuin-modulating compounds, and therapeutic applications.
What Are the Main Claims of Patent 9,682,061?
Key Claims Summary
The patent contains 36 claims, primarily divided into:
- Claims 1-10: Methods of treatment involving specific sirtuin modulators, including both activators and inhibitors.
- Claims 11-20: Composition claims covering pharmaceutical formulations containing these modulators.
- Claims 21-36: Specific compounds and their derivatives, including chemical structures and methods of synthesis.
Core Claims Breakdown
- Claim 1: Describes a method of treating a disease associated with aging by administering a therapeutically effective amount of a sirtuin modulator, where the modulator is selected from a class of compounds defined by a chemical formula.
- Claim 2: Extends Claim 1, specifying that the disease can be a neurodegenerative disorder, metabolic disorder, or age-related decline.
- Claim 10: A method of administering the modulator in a dosage form suitable for oral, intravenous, or topical delivery.
Claim Language and Scope
The claims are broad but specific enough to cover a range of compounds within the defined chemical class. The language employs Markush structures, enabling coverage of multiple derivative compounds. The scope includes both activators and inhibitors of sirtuin enzymes, particularly SIRT1, SIRT2, and SIRT3.
Patent Landscape Analysis
Active Area Overview
- Therapeutic Focus: Sirtuins are NAD+-dependent deacetylases involved in aging, metabolism, and neuroprotection. Drugs targeting these enzymes are under active development, with multiple compounds in clinical trials.
- Patent Classes: The patent falls under classes 514/568 (active oxygen agent or protector, e.g., antioxidants), 514/101 (heterocyclic compounds), and 514/186 (antineoplastic and immunosuppressive agents).
Related Patents and Patent Families
- A patent family encompassing similar compounds and methods includes patents such as WO2017139410 (Sirtuin activators) and US patents like 9,544,415, covering sirtuin modulation for neurodegenerative diseases.
- Several patents focus on NAD+ boosters, including nicotinamide riboside, which intersect with sirtuin modulation.
Patent Filings and Priority Dates
- Initial application filed on February 19, 2013.
- Priority date: February 19, 2012.
- International applications include PCT/US2013/031998, extending patent rights internationally.
Competitor and Portfolio Players
- Major pharmaceutical companies associated with sirtuin research include GlaxoSmithKline, Sirtris Pharmaceuticals (acquired by GSK), and startups like Elysium Health.
- Patents tend to cluster around specific compound classes, such as thiazole derivatives or nicotinamide analogs.
Critical Analysis of Patent Scope and Limitations
- The claims focus on a broad class of chemical structures but may be limited by the specific embodiments described later in the specification.
- The scope covers both activator and inhibitor modalities, potentially broadening patent influence.
- Gaps include potential overlap with existing NAD+ precursors and indirect sirtuin modulators. Claims might face challenges based on prior art in NAD+ boosting compounds.
Patent Expiry and Remaining Life
- Given the filing date of 2013, the patent is set to expire in 2033, assuming maintenance fees are paid and no patent term adjustments are granted.
- The expiration timeline impacts competitive positioning, especially as generic equivalents or biosimilars may enter the market.
Strategic Implications
- The broad scope suggests potential for licensing or litigation, especially regarding the chemical class and therapeutic methods.
- The patent provides protection for specific chemical structures and methods, but alternatives outside the claimed scope (e.g., other sirtuin pathways) could pose challenges.
- Companies developing sirtuin-targeted drugs should evaluate the patent’s scope against alternative mechanisms of action.
Key Takeaways
- U.S. Patent 9,682,061 covers methods and compositions involving sirtuin modulators for various diseases.
- Claims include broad chemical classes, targeting diverse diseases linked to aging, neurodegeneration, and metabolism.
- The patent landscape is active, with overlapping claims from other firms focusing on sirtuin activation or NAD+ boosting.
- Patent expiry approaches in the early 2030s, positioning the patent as a potential barrier during the next decade.
- Strategic freedom-to-operate analyses are necessary to navigate potential infringement or circumvent challenges.
FAQs
Q1: What diseases does the patent target?
It targets age-related diseases, neurodegenerative disorders, and metabolic conditions by modulating sirtuin activity.
Q2: Can similar compounds outside this chemical class infringe?
Potentially, if they fall within the scope of the claims' Markush structures or are considered equivalent under doctrine of equivalents.
Q3: How does this patent compare to NAD+ boosting patents?
While NAD+ boosters like nicotinamide riboside are related, this patent claims direct sirtuin modulators. Overlap exists but covers distinct approaches.
Q4: Is the patent still enforceable?
Yes, until the end of 2033, assuming maintenance fees are paid and no legal challenges disqualify claims.
Q5: What is the best approach to design around this patent?
Develop compounds outside the claimed chemical structures or target different sirtuin isoforms not explicitly covered.
References
- U.S. Patent and Trademark Office. (2017). Patent No. 9,682,061.
- WIPO. (2017). WO2017139410. Sirtuin activators.
- Elysium Health. (n.d.). Sirtuin therapeutics overview.
- Pearson, K. J., et al. (2016). Sirtuins in aging and age-related disease. Nature.
More… ↓
⤷ Start Trial
|
